DYAI

Dyadic is a two-decades-old gene-expression platform company that still has no products approved for sale — the 10-K states plainly that 'all our revenue to date has been research revenue from third-party collaborations and grants.' That revenue is tiny and going the wrong way: $3.09M in FY2025, down 11.6% YoY and below FY2024's $3.50M, on a business that loses money at an extraordinary rate. Operating margin is -232.8%, net income was -$7.36M (worse than FY2024's -$5.81M), and operating cash flow deteriorated 43.5% to -$5.70M. Against only $4.62M of cash (itself down 29%), the company has under one year of runway at the current burn — the classic setup for either a dilutive raise or a going-concern crisis, and the filing explicitly frames delisting as a threat to its 'ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern.'

The balance sheet is nearly hollowed out. Stockholders' equity collapsed 50.1% to $1.23M while liabilities grew 16.8% to $8.71M, pushing liabilities/equity to 7.07x and ROE to -597.6%. Accumulated deficit sits at -$93.5M. Shares outstanding already jumped 21.1% YoY to 36.4M, so existing holders are being diluted even before the next inevitable capital raise. Meanwhile the Nasdaq overhang is live and recurring: the company breached both the $35M MVLS and $1.00 minimum-bid tests in early 2025, cured them by October 2025, and was then hit with a *fresh* minimum-bid deficiency notice on December 19, 2025. At $0.94 (down 7.79% today) the stock is below the $1 threshold right now, and the $34.3M market cap is under the $35M MVLS line — both compliance clocks are effectively ticking again.